QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

INCY

QT78Incyte Corporation
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
98.22
-0.77-0.78%
OverviewShort InterestFilings
INCYQT78Incyte Corporation·NASDAQ
OverviewShort InterestFilings
98.22-0.78%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E13.78EPS (ttm)
7.08
Insider Own17.93%
Shs Outstand199.78M
Perf Week-8.91%
Market Cap19.78BForward P/E10.88EPS next Y9.02Insider Trans0.12%Shs Float-Perf Month2.74%
Enterprise Value16.35BPEG0.01EPS next Q1.80Inst Own-Short Float-Perf Quarter5.67%
Income1.44BP/S3.69EPS this Y6.37%Inst Trans-Short Ratio-Perf Half Y1.23%
Sales5.36BP/B3.55EPS next Y19.83%ROA19.51%Short Interest-Perf YTD-0.56%
Book/sh27.79P/C13.01EPS next 5Y-15.15%ROE29.31%52W High112.29 -12.53%Perf Year42.74%
Cash/sh20.10P/FCF13.63EPS past 3/5Y-ROIC20.13%52W Low66.74 47.17%Perf 3Y-
Dividend Est.-EV/EBITDA8.74Sales past 3/5Y14.83% 14.03%Gross Margin92.48%Volatility2.21% 2.58%Perf 5Y-
Dividend TTM-EV/Sales3.05EPS Y/Y TTM4860.00%Oper. Margin27.05%ATR (14)3.80Perf 10Y-
Dividend Ex-Date-Quick Ratio3.60Sales Y/Y TTM26.43%Profit Margin26.71%RSI (14)46.67Recom2.62
Dividend Gr. 3/5Y-Current Ratio3.68EPS Q/Q56.03%SMA20-1.64%Beta0.58Target Price109.80
Payout0.00%Debt/Eq0.01Sales Q/Q20.89%SMA500.05%Rel Volume2.47Prev Close98.99
Employees2,617LT Debt/Eq0.01EarningsAug 04SMA2001.47%Avg Volume1.64MPrice98.22
IPO DateNov 04, 1993Option/ShortYes / YesEPS/Sales Surpr.31.16% 4.69%Net Debt/EBITDA-1.83Volume4,034,585Change-0.78%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-10-26ReiteratedH.C. Wainwright$135 → $140
Jun-09-26ReiteratedStifel NicolausHold$120 → $123
Jun-08-26ReiteratedOppenheimerPerform$90 → $107
May-21-26InitiatedBernsteinMarket Perform$99
Apr-29-26ReiteratedOppenheimerPerform$82 → $90
Mar-16-26DowngradeJefferiesBuy → Hold
Feb-18-26ReiteratedBarclaysOverweight$116 → $117
Feb-11-26ReiteratedMorgan StanleyEqual Weight$94 → $102
Feb-11-26ReiteratedStifel NicolausHold$119 → $120
Feb-06-26ReiteratedPiper SandlerOverweight$102 → $110
Latest News
Jun-18-26
Jun-18-2606:53AM
Abivax: Safety Signals Loom Ahead Of The NDA SubmissionSeekingAlpha
Jun-17-26
Jun-17-2610:47AM
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)Yahoo
Jun-15-26
Jun-15-2607:05PM
Top S&P500 movers in Monday's sessionChartMill
04:35PM
Monday's session: top gainers and losers in the S&P500 indexChartMill
02:43PM
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA ReviewYahoo
02:35PM
Which S&P500 stocks are gapping on Monday?ChartMill
03:20AM
Reported Saturday, Incyte's Phase 3 FrontMIND Trial Shows Tafasitamab Plus Lenalidomide And R-CHOP Reduces Risk Of Disease Progression Or Death By 25% In Previously Untreated High-Risk DLBCL And HGBLBenzinga
03:14AM
Reported Saturday, Incyte's First-In-Class INCA033989 Achieves 87% Hematologic Response In ET And 55% Spleen Volume Reduction In MF With Consistent Molecular Activity Across Both Diseases At EHA 2026Benzinga
02:53AM
Reported Sunday, Mirum Pharmaceuticals And Incyte Report Pivotal Phase 2 PROGRESS Study Results For Zilurgisertib Showing 99.9% Reduction In New HO Lesion Volume In Fibrodysplasia Ossificans Progressiva Patients At Week 24Benzinga
Jun-14-26
Jun-14-2608:35PM
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans ProgressivaYahoo
Jun-13-26
Jun-13-2603:15PM
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential ThrombocythemiaYahoo
10:00AM
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free SurvivalYahoo
Jun-12-26
Jun-12-2603:12AM
Incyte Buys Vega To Add Late Stage Von Willebrand Disease OpportunityYahoo
Jun-11-26
Jun-11-2605:48PM
Incyte Nears Buy Point As $1.25 Billion Acquisition Expands OfferingsYahoo
Jun-10-26
Jun-10-2608:33PM
Why Incyte (INCY) Stock Is Up TodayYahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue5,3625,1414,241
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A404372312
Gross Profit4,9584,7693,929
Selling, General and Administrative Excl. Other1,3781,3761,222
Research and Development2,1292,0502,607
Other Operating Expense10-1
Operating Income1,4501,343101
Interest Expense422
Unusual Expense
———
Non-Operating Income (Expense)-327-324-218
Net Income Before Taxes1,7741,664317
Income Taxes342378284
Consolidated Net Income1,4311,28733
Net Income From Continuing Operations1,4311,28733
Net Income1,4311,28733
EPS (Recurring)7.306.590.16
EPS (Basic, Before Extraordinaries)7.306.590.16
EPS (Diluted)7.086.410.15
EBITDA1,8721,760408
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio13.8715.41—
Price To Sales Ratio3.653.75—
Gross Margin92.4792.7692.64
Operating Margin27.0426.122.38
Net Margin26.6925.030.78
Shares Outstanding199195207
Market Capitalization19,54619,260—
Operating Lease Expense
———
Insider Trading Volume
$102.25$96.92$91.60$86.28$80.95● Close Price0.00M5.19M10.38M15.57M20.77MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Tray ThomasPrincipal Accounting OfficerJun 04 '26Option Exercise83.835,278442,45423,771Jun 08 12:00 AM
Tray ThomasPrincipal Accounting OfficerJun 04 '26Sale100.002,639263,90021,132Jun 08 12:00 AM
Tray ThomasPrincipal Accounting OfficerMay 26 '26Sale97.352,051199,66521,132May 28 12:00 AM
BIENAIME JEAN JACQUESDirectorMay 26 '26Option Exercise84.5330,0002,535,90035,841May 28 12:00 AM
Clancy Paul JDirectorMay 19 '26Option Exercise84.5330,0002,535,90038,741May 21 12:00 AM
Clancy Paul JDirectorMay 19 '26Sale94.9315,0001,423,95023,741May 21 12:00 AM
BAKER BROS. ADVISORS LPdirector, 10 percent owner:May 08 '26Option Exercise84.5345,0003,803,85028,203,718May 11 12:00 AM
CAGNONI PABLO JPresident, Global Head of R&DApr 17 '26Option Exercise69.4337,3342,592,092281,359Apr 21 12:00 AM
CAGNONI PABLO JPresident, Global Head of R&DApr 17 '26Sale96.5018,6671,801,366262,692Apr 21 12:00 AM
Meury Williamdirector, officer, other: Chief Executive OfficerApr 15 '26Option Exercise0.00125,0000161,101Apr 17 12:00 AM
CAGNONI PABLO JPresident, R&DMar 17 '26Option Exercise63.0737,3342,354,710253,467Mar 19 12:00 AM
CAGNONI PABLO JPresident, R&DMar 17 '26Sale94.2418,6671,759,178234,800Mar 19 12:00 AM
CAGNONI PABLO JPresident, R&DFeb 19 '26Option Exercise61.5937,3362,299,406253,468Feb 23 12:00 AM
CAGNONI PABLO JPresident, R&DFeb 19 '26Sale100.9118,6681,883,788234,800Feb 23 12:00 AM
Issa Mohamed KhairieEVP, Head of US OncologyJan 07 '26Sale109.0710,8561,184,06466,132Jan 08 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR